US FDA refuses to review anti-cancer drug Soligenix

The U.S. Food and Drug Administration refused to consider Soligenix’s application to approve its cancer treatment, the drug developer said Tuesday, sending its stock down more than 30%.

Share this post:

Related Posts
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
WordPress Cookie Plugin by Real Cookie Banner